Details of Drug-Drug Interaction
| Drug General Information (ID: DDIR3GKPLA) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Prilocaine | Drug Info | Mepivacaine | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anesthetics | Anesthetics | |||||||
| Structure | |||||||||
| Mechanism of Prilocaine-Mepivacaine Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of methemoglobinemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Prilocaine | Mepivacaine | |||||||
| Mechanism | Methemoglobinemia | Methemoglobinemia | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Methemoglobinemia | ||||||||
| Factor Description | Methemoglobinemia is a condition in which higher than normal levels of methemoglobin are found in the blood. Methemoglobinemia is a potentially life-threatening condition in which the oxygen-carrying capacity of circulating hemoglobin is reduced due to the conversion of some or all of the four iron species from the reduced ferrous (Fe2+) state to the oxidized iron (Fe3+) state. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Prilocaine should be used with caution in the presence of other methemoglobin-inducing drugs. Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with prilocaine. Methemoglobin levels should be monitored and oxygen administered whenever possible. Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds nausea headache dizziness lightheadedness lethargy fatigue dyspnea tachypnea tachycardia palpitation anxiety and confusion. | ||||||||